A first-in-Asian phase 1 study to evaluate safety, pharmacokinetics and clinical activity of VS-6063, a focal adhesion kinase (FAK) inhibitor in Japanese patients with advanced solid tumors

PURPOSE: VS-6063 (also known as defactinib or PF-04554878) is a second-generation inhibitor of focal adhesion kinase and proline-rich tyrosine kinase-2. This phase 1 study evaluated the safety and tolerability, pharmacokinetics, and clinical activity of VS-6063 in Japanese subjects with advanced sol...

Descripción completa

Detalles Bibliográficos
Autores principales: Shimizu, Toshio, Fukuoka, Kazuya, Takeda, Masayuki, Iwasa, Tutomu, Yoshida, Takeshi, Horobin, Joanna, Keegan, Mitchell, Vaickus, Lou, Chavan, Ajit, Padval, Mahesh, Nakagawa, Kazuhiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4844649/
https://www.ncbi.nlm.nih.gov/pubmed/27025608
http://dx.doi.org/10.1007/s00280-016-3010-1

Ejemplares similares

Ejemplares similares